New combo aims to wipe out aggressive breast cancer before surgery
NCT ID NCT07342283
First seen Jan 21, 2026 · Last updated May 07, 2026 · Updated 15 times
Summary
This study tests whether adding the drug QL1706 to standard chemotherapy before surgery can completely eliminate triple-negative breast cancer in 30 patients with stage II or III disease. Participants receive 8 cycles of treatment over about 6 months, followed by surgery. The main goal is to see how many have no cancer left at the time of surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE-NEGATIVE BREAST CANCER (TNBC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Affiliated Hospital of Nantong University
RECRUITINGNantong, Jiangsu, China
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.